Chia-Ching C.

Chia-Ching C. has extensive work experience in the field of scientific research. They began their career in 1999 as a Medical Assistant in the military, where they also became a certified Emergency Medical Technician. In 2001, they worked as a Research Assistant at the National Yang Ming University, where they were responsible for establishing a proteomic tool for analyzing Homo sapiens phosphatase.

Chia-Ching then joined Rutgers University in 2002 as a Rutgers-UMDNJ Joint Program of Molecular Biosciences Fellow. Here, they assisted in various projects, including isolating the suppressor of rna14-2 and establishing interactions between Rna14p and TFIIB. They also developed Sir2p and Sir3p chimera to restore yeast mating phenotype defects and established a protocol to isolate yeast nuclear membrane protein.

In 2003, Chia-Ching joined the UMDNJ-RWJMS Department of Pharmacology as a Research Assistant. In this role, they determined mechanisms of Sir2 protein function in transcription regulation and engineered genes to regulate transcription through epigenetic modifications and repressed genome structure in a model organism.

From 2009 to 2017, Chia-Ching worked at Rutgers University. They initially served as a Post-Doctoral Research Associate, where they characterized the contribution of Sirtuins functions in genome stability, developed microorganism genome engineering tools, and identified functional interacting partners of Esc1. Later, Chia-Ching became a Research Associate III and focused on developing a high sensitivity assay for rDNA locus cohesion, creating a yeast benchwork toolbox, and characterizing the effects of rDNA transcription and associated proteins in genome stability.

In 2017, Chia-Ching joined Abcam as a Research Scientist I, where they performed research related to genomic stability and function. From 2019 to 2020, they held the position of Senior Scientist at Abcam, continuing their work in genomic stability.

In 2020, Chia-Ching joined Abalone Bio as a Senior Scientist, where they remained until 2021. They then joined Dynamicure Biotechnology in 2021 as a Senior Scientist, focusing on their expertise in scientific research.

In 2022, Chia-Ching became a Principal Scientist at Immunitas Therapeutics, where they utilized their skills and knowledge in scientific research until 2023.

Finally, in 2023, Chia-Ching joined Leveragen as a Principal Scientist, continuing their career in scientific research.

Chia-Ching C. has a diverse education history that includes degrees and certifications in various fields. They completed the Data Science Specialization program offered by Johns Hopkins University through Coursera in 2014-2015. In 2010-2011, Chia-Ching earned an MBA from the University of Phoenix, specializing in Business Administration and Management. Prior to that, between 2003 and 2008, they obtained a Ph.D. in Cellular and Molecular Pharmacology from the University of Medicine and Dentistry of New Jersey. In 2002-2003, Chia-Ching studied Molecular Biosciences at Rutgers University. They also hold a Master's degree in Biopharmaceutical Science from National Yang Ming University, which was completed in 1999. In 1997, they received a Bachelor of Science degree in Agriculture Chemistry from National Taiwan University. In terms of additional certifications, Chia-Ching completed the HAVEN Leadership Foundations | Level 1 Leadership program offered by HAVEN Human Asset Ventures in March 2023. They also obtained the Capstone: Retrieving, Processing, and Visualizing Data with Python certification through Coursera in February 2020. Additionally, Chia-Ching holds a Data Science Specialization certification from Coursera Verified Certificates, which was obtained in May 2015. There is also a mention of completion of a Canvas- mini medical school program, although no specific years or details are provided. Lastly, Chia-Ching attended junior high school, but no specific time frame or other information is given about this stage of education.